Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
We found that pediatric brain tumors (medulloblastoma and glioblastoma) and retinoblastoma express GD2 highly. Next, we manufactured GD2-specific chimeric antigen receptor-transducted T cell (GD2 CAR-T cell) with piggyBac transposon system which is a non-viral gene transduction method. GD2 CAR T cell killed GD2-positive tumor cell lines dramatically in vitro. We searched combination drugs to enhance the antirtumor ability of the GD2 CAR T cell. We found that histone deacetylase inhibitors, vorinostat, can enhance the antitumor ability of the GD2 CAR T cell.
|